Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas
- 18 August 2009
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 50 (9), 1500-1508
- https://doi.org/10.2967/jnumed.108.060426
Abstract
The CD20 cell surface antigen is expressed at high levels by over 90% of B-cell non-Hodgkin lymphomas (NHL) and is the target of the anti-CD20 monoclonal antibody rituximab. To provide more sensitive, tumor-specific PET imaging of NHL, we sought to develop PET agents targeting CD20. Methods: Two recombinant anti-CD20 rituximab fragments, a minibody (scFv-CH3 dimer; 80 kDa) and a modified scFv-Fc fragment (105 kDa), designed to clear rapidly, were generated. Both fragments were radiolabeled with 124I, and the minibody was additionally labeled with 64Cu (radiometal) after conjugation to 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′′′-tetraacetic acid (DOTA). The radioiodinated fragments and the radiometal-labeled minibody were evaluated in mice as small-animal PET imaging agents for the in vivo imaging of human CD20–expressing lymphomas. Results: Rapid and specific localization to CD20-positive tumors was observed with the radioiodinated fragments. However, the tumor uptake levels and blood activities differed, resulting in different levels of contrast in the images. The better candidate was the minibody, with superior uptake (2-fold higher than that obtained with scFv-Fc) in CD20-positive tumors and low uptake in CD20-negative tumors. Ratios of CD20-positive tumors to CD20-negative tumors at 21 h were 7.0 ± 3.1 (mean ± SD) and 3.9 ± 0.7 for the minibody and scFv-Fc, respectively. The ratio achieved with the 64Cu-DOTA-minibody at 19 h was about 5-fold lower because of higher residual background activity in CD20-negative tumors. Conclusion: A radioiodinated minibody and a radioiodinated scFv-Fc fragment produced excellent, high-contrast images in vivo. These new immunoPET agents may prove useful for imaging CD20-positive lymphomas in preclinical models and in humans with NHL.Keywords
This publication has 46 references indexed in Scilit:
- Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing TumorsClinical Cancer Research, 2008
- Antibodies for Molecular Imaging of CancerThe Cancer Journal, 2008
- Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragmentNature Protocols, 2006
- Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments forIn vivoImagingCancer Research, 2005
- Humanization of the anti-CEA T84.66 antibody based on crystal structure dataProtein Engineering, Design and Selection, 2004
- Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromesVox Sanguinis, 2003
- Tumor Targeting of Radiometal Labeled Anti-CEA Recombinant T84.66 Diabody and T84.66 Minibody: Comparison to Radioiodinated FragmentsBioconjugate Chemistry, 2001
- Radioiodinated Antibody Targeting of the HER-2/neu OncoproteinNuclear Medicine and Biology, 1997
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Analytic 3D image reconstruction using all detected eventsIEEE Transactions on Nuclear Science, 1989